Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

International Symposium on Pancreatic Disease Headed Up by Hadassah Specialist

Earlier this month, Jerusalem hosted an international symposium dealing with inherited diseases of the pancreas. The symposium was organized by Prof. Michael Wilschanski, Director of Hadassah’s Pediatric Gastroenterology Unit, along with Prof. Markus M. Lerch of Greifswald University Hospital, Germany, and Prof. David C. Whitcomb of the University of Pittsburgh, PA.

Among the presenters from Canada, France, Germany, Israel, Norway, Spain, and the United States were physicians who specialize in identifying genes that are related to chronic diseases of the pancreas. Several presentations addressed aspects of the CFTR gene (Cystic Fibrosis Transmembrane Conductance Regulator), which provides instructions for making a protein called the cystic fibrosis transmembrane conductance regulator. This protein functions as a channel across the membrane of cells that produce mucus, sweat, saliva, tears, and digestive enzymes. Disease-causing mutations in the CFTR gene alter the production, structure or stability of this channel and prevent the channel from functioning properly. They impair the transport of chloride ions and the movement of water into and out of cells so that the cells that line the passageways of the lungs, pancreas, and other organs produce mucus that is abnormally thick and sticky. The abnormal mucus, in turn, obstructs the airways and glands.

Symposium topics included “25 Years of the CFTR Discovery”; Compound CFTR and other Mutations in Children”; “Genotype, Phenotype, and Functional Correlations of CFTR Mutations”; and “The Role of CFTR Mutations in Pancreatitis.”

Prof. Wilschanski, in his presentation, presented his recent research findings regarding “Therapeutic Approaches to Correct CFTR Dysfunction,” which were published in the May 14 issue of Lancet Respiratory Medicine.The article, coauthored with Prof. Eitan Kerem, head of Hadassah’s Pediatrics Division, and other global colleagues, describes a study conducted over a number of years with patients from 36 sites in 11 countries in North America and Europe, which explored the safety and efficacy of the drug, ataluren, in cystic fibrosis patients who have “nonsense mutations.” This category of mutation refers to a change in the DNA that prematurely stops the reading of messenger RNA (mRNA), resulting in a polypeptide chain that ends prematurely and a protein product that is incomplete and usually nonfunctional. Ataluren was developed to restore functional protein production in genetic disorders caused by nonsense mutations—which, in turn, are the cause of cystic fibrosis in 10 percent of patients. The authors note that their research indicates ataluren “might be beneficial for patients who are not taking chronic inhaled tobramycin.”

Others aspects of pancreatic disease discussed at the symposium were the genetics of pancreatic pain, genetic predispositions to pancreatic cancer, and molecular genetics in pancreatic cancer.

Date: 6/25/2014

Hadassah Stem Cell Expert Speaks at TEDx Conference in Jaffa

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Hadassah Physicians Receive Prestigious Grants and Awards

New Research at Hadassah: Computational Tools Unravel the Mystery of Transient Amnesia

From Life-Threatening Brain Bleed to Birth of a Daughter

Cookbook Author, Rabbi Marks, Spends Last Days at Hadassah's Hospice

Hadassah’s Revolutionary Tipat Halav Clinics of 1920s Featured in Jerusalem Old City Museum

Victims of Terror Share Their Stories of Anguish and Appreciation with Hadassah President

Hadassah’s Advanced Gene Sequencing Changes the Life of a Family from Uzbekistan

IDF Medic Heroically Battles Terrorist, Both Treated at Hadassah

Orthopedic Trauma Turns Tragedy into Innovation at Hadassah

On the Cutting-Edge of Melanoma Treatment: Hadassah’s Protocols and Research

Saving a Newborn from a Life Without Sight

Terrorist and Victim Sent to Hadassah's Hospitals After Third Attack in Two Weeks

Three Sent to Hadassah After Second Jerusalem Terror Attack of the Week

Clinical Trial of Hadassah-Developed Stem Cell Treatment for Macular Degeneration Gets Go-Ahead from FDA

“We Don’t Say ‘No’,” Hadassah Neurosurgeon Explains in Operating on 82-Year-Old Patient

Cutting-Edge Medicine and Research; a Role Model for Peace: A Briefing from the Hospital's Director General

4 Ways Hadassah Hospital is Preparing for Ebola—Just in Case

Hailing from 17 Countries: the 39th Graduation Class of Hadassah’s International Master of Public Health Program

More hMedicine Stories

Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America